One 5% yielder I’d consider over GlaxoSmithKline plc

Are you considering alternative dividend picks amid an earnings plateau at GlaxoSmithKline plc (LON:GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 100 pharmaceutical giant GlaxoSmithKline (LSE: GSK) faces a number of challenges in 2018.

With the drug maker unlikely to emerge from its earnings plateau for some time, amid growing competitive pressures in its HIV and respiratory businesses, there’s growing concern about the sustainability of its dividends.

Dividend frozen at 80p

GSK has frozen its annual dividend per share at 80p since 2015, but still it has struggled to generate enough profits and free cashflow to afford its current level of shareholder payouts. Net debt has climbed from £10.7bn at the end of 2015 to £14.2bn by the end of September 2017.

And although free cashflow has improved significantly in recent months, thanks to a positive currency benefit and the launch of new products, the company’s financial flexibility could come under pressure as it ponders the acquisition of Pfizer’s consumer health unit.

Little earnings movement

The earnings plateau is expected to continue for some time ahead, as the impact of new product launches is expected to be offset by the legacy effects of patent losses on key products like respiratory drug Advair. Although City analysts expect underlying earnings to have grown by 8% this year, they expect a 3% reversal this year. And for 2019, they think there will be a rebound in its bottom line of just 4%.

Although valuations aren’t pricey, with the shares trading at just 12.2 times expected earnings this year, the risk of a dividend cut continues to overhang its shares. As such, GSK’s current 6.1% dividend doesn’t tempt me right now.

A better pick

Instead, I reckon automotive, cycling and leisure retailer Halfords (LSE: HFD) represents a better dividend pick. In my view, the company has better fundamentals which give it a positive earnings outlook — an important criterion for dividend growth.

Halfords reported a 3.2% increase in sales over the 15 weeks to January 12, after strong trading in its cycling division. Like-for-like sales at its car maintenance division were also positive, with sales up 2.1% over the same period on improved car headlamp bulb and de-icer sales.

However, on the downside, Halfords cautioned that it expects the UK retail environment to “remain subdued” and warned that it would face higher costs because of the weaker pound. But I’m still more sanguine about its earnings prospects, due to the positive top-line picture, with growing like-for-like sales, and new store openings in the UK and in Europe.

Defensive appeal

In addition, unlike most retail stocks, Halfords is an intrinsically defensive stock. This is because car maintenance and repair, a non-cyclical business, makes up around 70% of revenues. After all, customers can’t avoid taking their cars for their annual MOT or conducting necessary repairs, due to legal requirements and the need to the keep their vehicles in good working order.

Halfords’ earnings multiples are similar to GSK’s, with shares in the retailer trading on 12.2 times expected earnings this year. And on top of this, the stock yields 5.1%

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »